James P Allison Selected Research

CTLA-4 Antigen

1/2022	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
8/2013	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
4/2012	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
10/2011	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
4/2011	Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
12/2008	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
2/2008	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
7/2003	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
4/2003	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James P Allison Research Topics

Disease

121	Neoplasms (Cancer) 01/2022 - 07/2002
44	Melanoma (Melanoma, Malignant) 12/2021 - 04/2003
21	Prostatic Neoplasms (Prostate Cancer) 10/2021 - 01/2003
6	Carcinoma (Carcinomatosis) 12/2020 - 04/2003
5	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2005
5	Inflammation (Inflammations) 01/2018 - 01/2003
4	Disease Progression 01/2021 - 11/2013
4	Breast Neoplasms (Breast Cancer) 12/2016 - 01/2005
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2019
3	Colitis 01/2022 - 12/2018
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021 - 01/2019
3	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 02/2012
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2020
3	Experimental Melanoma 03/2014 - 03/2010
3	Testicular Neoplasms (Testicular Cancer) 10/2013 - 10/2011
3	Necrosis 01/2013 - 04/2003
3	Adenocarcinoma 04/2012 - 01/2008
2	Squamous Cell Carcinoma of Head and Neck 04/2022 - 01/2021
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 03/2002
2	Pathologic Complete Response 01/2021 - 09/2019
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 02/2008
2	Virus Diseases (Viral Diseases) 01/2020 - 10/2014
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019 - 04/2007
2	Adenocarcinoma of Lung 10/2017 - 08/2015
2	Brain Neoplasms (Brain Tumor) 01/2017 - 10/2012
2	Exanthema (Rash) 12/2016 - 03/2007
2	Autoimmune Diseases (Autoimmune Disease) 01/2016 - 05/2009
2	Fibrosis (Cirrhosis) 09/2015 - 01/2013
2	Glioma (Gliomas) 10/2012 - 04/2007
2	Infections 05/2009 - 07/2005
1	Enterocolitis 01/2022
1	Granuloma 01/2021
1	Myocarditis (Carditis) 01/2021
1	COVID-19 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 01/2020

Drug/Important Bio-Agent (IBA)

29	AntigensIBA 01/2020 - 01/2003
28	IpilimumabIBA 01/2021 - 03/2007
20	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2014
17	AntibodiesIBA 01/2020 - 04/2003
14	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2012
13	Monoclonal AntibodiesIBA 11/2014 - 02/2005
9	CTLA-4 AntigenIBA 01/2022 - 04/2003
8	LigandsIBA 01/2019 - 01/2003
8	VaccinesIBA 11/2014 - 04/2003
7	CytokinesIBA 01/2020 - 05/2010
7	Neoplasm Antigens (Tumor Antigens)IBA 12/2016 - 03/2008
7	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 04/2011 - 04/2003
6	NivolumabIBA 01/2022 - 04/2016
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 04/2004
6	Peptides (Polypeptides)IBA 09/2015 - 03/2002
6	EpitopesIBA 11/2014 - 01/2006
5	Immunoglobulin G (IgG)IBA 01/2019 - 01/2005
4	Biological ProductsIBA 10/2017 - 07/2002
4	Cancer VaccinesIBA 10/2009 - 04/2003
3	tremelimumabIBA 11/2021 - 01/2019
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2021 - 10/2016
3	AndrogensIBA 10/2016 - 01/2003
3	AutoantigensIBA 01/2008 - 07/2003
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2016
2	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2020
2	Gemcitabine FDA Link 01/2021 - 06/2014
2	sipuleucel-T (APC8015)FDA Link 01/2021 - 10/2011
2	AutoantibodiesIBA 10/2019 - 11/2013
2	InterferonsIBA 01/2017 - 10/2012
2	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 04/2004
2	pembrolizumabIBA 04/2016 - 01/2016
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 10/2015 - 08/2011
2	Protein Subunit VaccinesIBA 09/2015 - 11/2014
2	Oncogene Proteins (Oncogene Protein)IBA 09/2015 - 08/2011
2	Mutant Proteins (Protein, Mutant)IBA 11/2014 - 02/2012
2	Therapeutic UsesIBA 03/2014 - 08/2009
2	EnzymesIBA 10/2013 - 08/2011
2	flt3 ligand protein (flt3 ligand)IBA 10/2012 - 10/2009
2	Interleukin-15 (Interleukin 15)IBA 06/2012 - 04/2012
2	Monophenol Monooxygenase (Tyrosinase)IBA 08/2011 - 04/2004
2	Differentiation AntigensIBA 04/2004 - 04/2003
1	sitravatinibIBA 01/2022
1	Dietary Fiber FDA Link 12/2021
1	Abatacept (Orencia)FDA Link 01/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Leucine (L-Leucine)FDA Link 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 12/2020
1	durvalumabIBA 12/2020
1	Neutralizing AntibodiesIBA 01/2020
1	SARS-CoV-2 spike proteinIBA 01/2020
1	Nucleocapsid ProteinsIBA 01/2020

Therapy/Procedure

73	Therapeutics 01/2022 - 01/2003
54	Immunotherapy 04/2022 - 07/2002
5	Cryosurgery 11/2021 - 01/2012
5	Radiotherapy 01/2021 - 03/2012
3	Drug Therapy (Chemotherapy) 10/2021 - 10/2016
3	Castration 10/2021 - 01/2020
3	Aftercare (After-Treatment) 01/2020 - 01/2005
2	Stem Cell Transplantation 10/2021 - 01/2018
2	Fecal Microbiota Transplantation 01/2019 - 12/2018
2	Precision Medicine 01/2017 - 01/2016
2	Immunomodulation 01/2017 - 08/2013
1	Neoadjuvant Therapy 12/2020
1	Combined Modality Therapy 12/2019